165 related articles for article (PubMed ID: 31975354)
1. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Weitz JI; Raskob GE; Spyropoulos AC; Spiro TE; De Sanctis Y; Xu J; Lu W; Suh E; Argenti D; Yang H; Albanese J; Lipardi C; Barnathan ES
Thromb Haemost; 2020 Mar; 120(3):515-524. PubMed ID: 31975354
[TBL] [Abstract][Full Text] [Related]
2. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
[TBL] [Abstract][Full Text] [Related]
3. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Spyropoulos AC; Lipardi C; Xu J; Lu W; Suh E; Yuan Z; Levitan B; Sugarmann C; De Sanctis Y; Spiro TE; Barnathan ES; Raskob GE
Clin Appl Thromb Hemost; 2019; 25():1076029619886022. PubMed ID: 31746218
[TBL] [Abstract][Full Text] [Related]
4. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Spyropoulos AC; Raskob GE; Cohen AT; Ageno W; Weitz JI; Spiro TE; Lu W; Lipardi C; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard G; Steg PG; Sugarmann C; Barnathan ES
Circulation; 2022 May; 145(19):1471-1479. PubMed ID: 35389229
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
[TBL] [Abstract][Full Text] [Related]
7. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Cohen AT; Spiro TE; Spyropoulos AC; Desanctis YH; Homering M; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Tapson VF; Burton P;
J Thromb Haemost; 2014 Apr; 12(4):479-87. PubMed ID: 24460645
[TBL] [Abstract][Full Text] [Related]
8. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
[TBL] [Abstract][Full Text] [Related]
10. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
[TBL] [Abstract][Full Text] [Related]
11. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
Lipardi C; Elliott CG; Sugarmann CL; Haskell L; Spyropoulos AC; Raskob GE; Xu J; Lu W; Marsigliano J; Spiro T; Yuan Z; Wu S; Barnathan ES
Clin Appl Thromb Hemost; 2021; 27():10760296211053316. PubMed ID: 34719984
[No Abstract] [Full Text] [Related]
12. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
[TBL] [Abstract][Full Text] [Related]
13. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
15. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Turpie AG; Wildgoose P; Yusen RD
J Thromb Thrombolysis; 2006 Aug; 22(1):31-8. PubMed ID: 16786230
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
17. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Mebazaa A; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Merli G; Schellong SW; Spyropoulos AC; Tapson VF; De Sanctis Y; Cohen AT
Circulation; 2014 Jul; 130(5):410-8. PubMed ID: 24970782
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
Ageno W; Lopes RD; Goldin M; Yusen RD; Albers GW; Elliott GC; Halperin JL; Hiatt WR; Maynard G; Steg PG; Weitz JI; Suh E; Lu W; Barnathan ES; Raskob GE; Spyropoulos AC
J Thromb Haemost; 2021 Nov; 19(11):2772-2780. PubMed ID: 34314574
[TBL] [Abstract][Full Text] [Related]
19. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Spyropoulos AC; Lipardi C; Xu J; Peluso C; Spiro TE; De Sanctis Y; Barnathan ES; Raskob GE
TH Open; 2020 Jan; 4(1):e59-e65. PubMed ID: 32190813
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
